Slide 1

Technically Sound. Objectively Better.

Investor PresentationJeffrey L. Dalsin / CEO1The Echometrix VisionTo disrupt traditional approaches to diagnostic imaging while lowering costs and improving patient outcomes2

Echometrix TeamShawn Guse, J.D.CEO of Intuitive Biosciences, Fmr. CEO of CPAC, Fmr. VP and Gen. Counsel at TomotherapyJanet A. LippincottFmr. Marketing and Commercialization lead at GE HealthcareBoard of DirectorsManagement TeamDaniel Malone, M.D.Internist/RheumatologistMSK Ultrasound expertSabrina Brounts, D.V.M., Ph.D.Developer of Echosoft equine useInternational demonstration of EchosoftBarbara Israel, Ph.D. Co-founder, Fmr. CEO of Platypus Tech, Secured $20M in federal grants, $3M in equity financingRay Vanderby, Ph.D. Co-founder, Director of Orthopedic Res at UW Madison 3Clinical Advisors

Jeffrey L. Dalsin, Ph.D. - CEOFmr. Dir. of Product Development at Nerites Corp.Nerites sold for $20M in 2011 Kenneth Lee, M.D., M.B.A. - CMODirector of MSK Ultrasound at UW Hospitals and Clinics

The Market: Unmet Clinical NeedsMuch opportunity for improvements to musculoskeletal (MSK) injury diagnosisPoint-of-care physicians have no diagnostic tool to make strained vs. torn assessmentNo tool to assess functional health status of injured tendon or ligamentPatients often referred to physical therapy without definitive diagnosisMRI is often requiredUltrasound is desireable, but no standard diagnostic approach exists

4The Market: Echosoft SolutionEchosoft will enable many improvements to soft tissue diagnosis and management Differential diagnosis (i.e., strained vs. torn)Provide objective measures during the healing process (i.e., degree of strain)Available at the point of careExams are a fraction of the cost of MRIUsable by all trained treating physicians

5Echosoft: Acoustoelasticity (AE) Applied to Biological Materials AnalogyTendons are like guitar stringsEach guitar string (tendon) has a specific pitch (echo signal)Pitch (echo signal) goes up with applied tension AE differentiates by material type (string 1 & 6) & material status (healthy or damaged)

PitchTension/stretch6th string1st stringDamaged 6th string6How Echosoft Works7

Proprietary algorithms

Compatible with all ultrasound hardware and images

ScanTrackComputeMapU.S. Patent 7,744,535, U.S. Patent 7,736,315, U.S. Patent Application 13/293499

Standard UltrasoundEchosoftStandard Ultrasound vs. Echosoft8

Click image to play movieClick image to play movieDiagnosis: Tendinopathy in Achilles9Achilles tendinopathic region identified

calcaneusAchilles tendonUnaffected region appears normalIn this case, a patient with a symptomatic Achilles tendon was scanned. The region suspected of Achilles tendinopathy and a region proximal to the affected area were analyzed. * The tendinopathic region demonstrated an abnormal color map, while:* the unaffected region appeared normal. The presence of a pathology was confirmed by the physician. 9Treatment Monitoring: Achilles Tendon10Abnormal color map (left) pre-treatment, resolves (right) with treatmentcalcaneusPatient with symptomatic Achilles tendon, pathology confirmed, treated by physicianStandard U/S

3 mo. post-treatment@ DiagnosisIn another case of Achilles tendinopathy, a patient with a symptomatic Achilles tendon was scanned upon original visit (left) and again following treatment (right). The color map returned towards normal, correlating to the resolution of pathology. 10Echosoft Value Proposition11Point-of-care diagnosisDecreased re-injury rateBetter careNew source of reimbursementDecreased diagnostic costsFewer repeat doctor visits

$1B MSK ultrasound market only 5-10% penetrated Echosoft: a catalyst for greater market penetrationCompetitive LandscapeEchosoft module + UltrasoundDiagnosticUltrasoundShear Wave ElastographyMRIPhysical ManipulationReal-Time ImagingPortablePoint-of-CareQuantifies Tissue FunctionReimbursed UseWidely Accepted Use in MSK12

Recent Milestones AchievedIdentified/fixed errors in algorithmsCode functioning in near-real timeCustomer Development ongoingCMO and Clinical Advisors Recruited$100k in new grant funding securedEchometrix has great momentum!131st company-owned patent to issueProduct Development: StatusStand-alone software package Prototype completeRuns on Windows computersClinical evaluation underwayTennis elbow (UW-Madison)Plantar fascia (UW-Madison)Rotator cuff (NYU)Achilles tendon (PanAm Clinic)

14

Product Development: Next PhaseReal-time, tablet enabled EchosoftAnalyze video stream from any ultrasound in real timeWireless image transmissionCompatible with all standard ultrasound systemsComplete solution for current ultrasound users (software and hardware included)15

Business Model16OfferingRevenue StreamsPhase 1Q1 2015Post-ProcessingEchosoft (Research and Veterinary Use)Initial License FeeAnnual Maint.

Phase 2Q3 2016Real-time Echosoft ModuleInitial PurchaseAnnual Maint.Phase/TimingPhase 3Q3-4 2016Partner License RoyaltiesU/S Hardware Intergration

Exit Strategy: Acquisition by PartnerExit through acquisition by medical imaging company anticipatedUltrasound ExitsLumenVuR2 TechnologiesSonositeZONAREExit Timing2007200620112013Exit Price$13.6 M$220 Million$995 M$105 MStatus at ExitPre-revenue and Pre-510K$45 M in Revenue$300 M in Revenue$64 M in RevenueExit MultipleN/A5x Revenue~3x Revenue1.6x RevenueAcquirerSonositeHologicFujiFilmMindray17Current StatusProof-of-concept studies completeRefined algorithmsStrong team, strong planDeveloping real-time functionEngaged experts and usersInvestmentSeeking up to $500,000 in debt financingEligible for Act 255 investor tax creditsUse of FundsComplete real-time prototypeClinical verification and validation testing of prototypeQuality system developmentRecruit CTOPrepare company for Series A VC investmentFundraisingReal-time PrototypeClinical Ver./Valid.PartneringExit$$510kCommercial DevelopmentSalesTechnically Sound. Objectively Better.

Jeffrey L. Dalsin, Ph.D. CEOjdalsin@echo-metrix.com708-955-8058

19